US Patent

US11944602 — Treatment of autoimmune disease in a patient receiving additionally a beta-blocker

Method of Use · Assigned to Novartis AG · Expires 2036-04-23 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating autoimmune diseases in patients who are also taking a beta-blocker using the drug siponimod.

USPTO Abstract

The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.

Drugs covered by this patent

Mayzent (SIPONIMOD) · Novartis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3889`	—	Mayzent
`U-3889`	—	Mayzent
`U-3889`	—	Mayzent

Patent Metadata

Patent number: US11944602
Jurisdiction: US
Classification: Method of Use
Expires: 2036-04-23
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.